Overall market sentiment has been high on Incyte Corporation (INCY) stock lately. INCY receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.
Incyte Corporation has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on INCY!
When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With INCY Stock Today?
Incyte Corporation (INCY) stock is higher by 0.26% while the S&P 500 is lower by -0.07% as of 11:44 AM on Friday, Dec 31. INCY has risen $0.19 from the previous closing price of $74.11 on volume of 723,884 shares. Over the past year the S&P 500 is higher by 27.95% while INCY is lower by -14.46%. INCY earned $2.41 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 30.77.
To screen for more stocks like Incyte Corporation click here.
More About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). Incyte's pipeline includes a broad array of oncology and dermatology programs.
Click Here to get the full Stock Report for Incyte Corporation stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
